Gilead Sciences, Inc. (TSX:GILD)
Canada · Delayed Price · Currency is CAD | Market Cap | 255.88B +30.6% |
| Revenue (ttm) | 43.25B +5.5% |
| Net Income | -4.60B |
| EPS | -3.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 17.33 |
| Dividend | 0.66 (2.20%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 1,633 |
| Open | 29.81 |
| Previous Close | 30.07 |
| Day's Range | 29.64 - 30.02 |
| 52-Week Range | 22.49 - 31.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest once-daily single tablet regimen for the treatment of HIV in adults who…
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment...
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), th...
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Health...
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of adult patients with unresectable, local...
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to ...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Gilead files automatic mixed securities shelf
17:08 EDT Gilead (GILD) files automatic mixed securities shelf
Gilead price target lowered to $150 from $156 at Truist
Truist lowered the firm’s price target on Gilead (GILD) to $150 from $156 and keeps a Buy rating on the shares. Gilead delivered a clean Q2 beat and raised guidance…
Gilead price target raised to $123 from $120 at RBC Capital
RBC Capital raised the firm’s price target on Gilead (GILD) to $123 from $120 and keeps a Sector Perform rating on the shares. The company delivered a solid quarter with…
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europ...
AHF Crowns Gilead Corporate Welfare King
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Gilead Sciences Earnings Call Transcript: Q2 2026
Base business sales grew 10% year-over-year, led by HIV, oncology, and liver disease. HIV sales rose 12%, with PrEP sales doubling and exceeding $1 billion quarterly. Raised full-year guidance for HIV and total product sales, while integrating major acquisitions and preparing for key product launches.
Gilead Sciences Earnings release: Q2 2026
Gilead Sciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Gilead Sciences Slides: Q2 2026
Gilead Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Gilead Sciences Quarterly report: Q2 2026
Gilead Sciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
Reports Q2 revenue $7.8B, consensus $7.4B. “Gilead (GILD) delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and…
Gilead second-quarter sales rise 8%, beating Wall Street estimates
Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs related to a series of acquisitions...
Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second qua...
Gilead update on California ruling removes an overhang, says UBS
UBS says Gilead (GILD) announced that the California Supreme Court ruled in the company’s favor in the state court on the final part of the ongoing TDF litigation and dismissed…
California's highest court rules for Gilead, says drugmakers don't have 'duty to innovate'
California's highest court ruled on Monday that manufacturers of drugs that are considered safe do not owe a duty to patients to try developing drugs that could be even safer, ruling in favor of Gil...
California's highest court rules for Gilead in 'duty to innovate' case
California's highest court on Monday ruled in favor of Gilead Sciences , in a case addressing whether manufacturers of drugs that are considered safe must try developing drugs that could be safer.
Gilead price target lowered to $145 from $155 at Barclays
Barclays lowered the firm’s price target on Gilead (GILD) to $145 from $155 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the biopharmaceuticals space…